Novartis AG (NYSE:NVS) Forecasted to Earn Q3 2025 Earnings of $2.12 Per Share

Novartis AG (NYSE:NVS - Free Report) - Equities researchers at Zacks Research raised their Q3 2025 earnings per share (EPS) estimates for Novartis in a research report issued to clients and investors on Tuesday, May 7th. Zacks Research analyst E. Bagri now anticipates that the company will post earnings of $2.12 per share for the quarter, up from their prior forecast of $1.98. The consensus estimate for Novartis' current full-year earnings is $7.26 per share.

A number of other research firms also recently weighed in on NVS. BMO Capital Markets increased their price target on shares of Novartis from $114.00 to $116.00 and gave the stock a "market perform" rating in a research note on Wednesday, April 24th. Morgan Stanley started coverage on Novartis in a research report on Tuesday, January 23rd. They issued an "equal weight" rating and a $114.00 target price on the stock.

Novartis Trading Up 1.9 %

Shares of NYSE NVS traded up $1.89 on Friday, reaching $102.10. 1,843,440 shares of the company traded hands, compared to its average volume of 1,847,700. The stock has a market capitalization of $208.69 billion, a PE ratio of 13.78, a P/E/G ratio of 1.56 and a beta of 0.53. Novartis has a fifty-two week low of $92.19 and a fifty-two week high of $108.78. The company has a current ratio of 0.90, a quick ratio of 0.71 and a debt-to-equity ratio of 0.43. The company has a 50 day moving average of $97.09 and a 200 day moving average of $99.07.

Novartis Increases Dividend

The firm also recently disclosed an annual dividend, which was paid on Thursday, March 7th. Shareholders of record on Friday, March 8th were paid a dividend of $3.7772 per share. This is an increase from Novartis's previous annual dividend of $3.47. This represents a yield of 3.1%. The ex-dividend date was Thursday, March 7th. Novartis's payout ratio is currently 32.79%.

Institutional Trading of Novartis

Several large investors have recently added to or reduced their stakes in NVS. Whittier Trust Co. boosted its stake in shares of Novartis by 0.8% in the third quarter. Whittier Trust Co. now owns 47,930 shares of the company's stock valued at $4,882,000 after purchasing an additional 381 shares during the period. TIAA Trust National Association acquired a new stake in shares of Novartis during the third quarter valued at about $725,000. Assetmark Inc. increased its position in shares of Novartis by 2.3% during the third quarter. Assetmark Inc. now owns 203,293 shares of the company's stock worth $20,707,000 after acquiring an additional 4,524 shares during the last quarter. First Trust Direct Indexing L.P. lifted its stake in shares of Novartis by 11.7% in the third quarter. First Trust Direct Indexing L.P. now owns 18,586 shares of the company's stock worth $1,893,000 after acquiring an additional 1,941 shares in the last quarter. Finally, Peoples Bank KS purchased a new position in Novartis in the third quarter valued at about $738,000. 13.12% of the stock is currently owned by institutional investors and hedge funds.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.